[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chinese PLA General Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":589},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,150,0,25,[9,49,73,107,124,151,173,197,216,234,257,282,307,330,350,371,391,408,435,457,478,499,524,546,568],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100644618","early-phase-1-gofast-car-t-cell-therapy-for-recurrent-refractory-b-cell-lymphoma-100644618",false,"NCT07670260","GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma","Exploratory Clinical Study of GoFast CAR T-Cell Platform Targeting CD19 CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma","Inclusion Criteria:\n\n* Age 18 years or older.\n* Histologically or cytologically confirmed primary refractory or relapsed\u002Fprogressive large B-cell lymphoma.\n* Expected survival of more than 3 months.\n* CD19-positive B-cell lymphoma confirmed by flow cytometry or immunohistochemistry.\n* ECOG performance status of 0 to 2 or KPS score greater than 80.\n* Adequate venous access for leukapheresis or peripheral blood collection, with no contraindication to blood cell separation.\n* White blood cell count ≥ 1 × 10\\^9\u002FL and lymphocyte count ≥ 0.3 × 10\\^9\u002FL.\n* INR \\\u003C 1.7 or prothrombin time prolonged by less than 4 seconds above the normal value.\n* ALT and AST ≤ 2.5 × upper limit of normal.\n* Total bilirubin ≤ 2.0 mg\u002FdL, equivalent to 34.2 μmol\u002FL.\n* Able to understand and voluntarily sign the written informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Active hepatitis B virus or hepatitis C virus infection.\n* HIV\u002FAIDS infection.\n* Any uncontrolled active infection.\n* Systemic corticosteroid use within 2 weeks before signing informed consent, except inhaled corticosteroids.\n* Active cardiac disease requiring treatment or poorly controlled hypertension.\n* Unstable or active ulcer disease or gastrointestinal bleeding.\n* History of organ transplantation or currently awaiting organ transplantation.\n* Central nervous system involvement by lymphoma.\n* Current participation in another clinical trial.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for this clinical study.","ALL","18 Years",{"count":20,"type":21},9,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","This is an investigator-initiated, prospective, open-label exploratory clinical study designed to evaluate the safety and preliminary efficacy of GoFast CD19 CAR T-cell therapy in adult patients with recurrent or refractory B-cell lymphoma. Eligible patients will undergo screening, baseline assessment, peripheral blood or leukapheresis collection, lymphodepleting chemotherapy, and intravenous infusion of GoFast CD19 CAR T cells. The study plans to enroll 9 participants using a sequential dose-escalation design. The primary outcome is objective response rate, and secondary outcomes include complete remission rate, overall survival, progression-related survival outcomes, duration of response, MRD negativity, and adverse events.",[27],"Relapsed or Refractory Large B-cell Lymphoma",[29,30,31,32,33,34,35],"CD19","CAR T-Cell Therapy","GoFast Platform","Large B-Cell Lymphoma","Relapsed or Refractory Lymphoma","Dose Escalation","Autologous CAR T Cells","NOT_YET_RECRUITING","2026-06-25",{"date":39,"type":40},"2026-06-26","ACTUAL",{"date":42,"type":21},"2026-06-30",{"date":44,"type":21},"2028-06-30",{"name":46,"class":47},"Chinese PLA General Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100642359","early-phase-1-the-safety-and-efficacy-of-allogeneic-cd70-car-t-therapy-in-unresectable-or-metastatic-clear-cell-renal-cell-carcinoma-100642359","NCT07645690","The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma","A Clinical Study to Evaluate the Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Patients With Unresectable or Metastatic Clear Cell Renal Cell Carcinoma","Key Inclusion Criteria:\n\n1.Age 18-75 years (inclusive), any gender. 2.Confirmed by histopathology and\u002For cytology as unresectable or metastatic clear cell renal cell carcinoma; 3.Local progression or metastasis after receiving at least second line therapy \\[including at least one immune checkpoint inhibitor (ICI) and at least one vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI)\\]; 4.Willing to undergo tumor tissue sample collection or provide previous tumor tissue samples for CD70 expression level testing; 5.Positive CD70 expression by immunohistochemical (IHC) staining of tumor tissue (percentage of positive cells ≥ 10%); 6.At least one measurable lesion according to RECIST v1.1 criteria. 7.Karnofsky Performance Status (KPS) ≥ 70%. 8.Organ function must meet the following criteria:\n\n1. Complete blood count (no G-CSF within 1 week prior to blood count testing. or no pegylated G-CSF within 2 weeks prior to blood count testing): Absolute neutrophil count (ANC) ≥ 1.0×10⁹\u002FL. platelet count (PLT) ≥ 100×10⁹\u002FL. hemoglobin ≥ 80 g\u002FL (excluding bone marrow suppression caused by lymphoma involvement of the bone marrow).\n2. Coagulation function: International normalized ratio (INR) ≤ 1.5×ULN, and activated partial thromboplastin time (APTT) ≤ 1.5×ULN.\n3. Liver function: Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3×ULN (if with liver metastasis, AST and ALT ≤ 5×ULN). total bilirubin ≤ 1.5×ULN.\n4. Renal function: Serum creatinine ≤ 1.5×ULN or creatinine clearance (Cockcroft-Gault formula) ≥ 60 mL\u002Fmin.\n5. Cardiac function: Left ventricular ejection fraction (LVEF) on echocardiography (ECHO) ≥ 50%, no pericardial effusion. no clinically significant abnormalities on 12-lead electrocardiogram (ECG).\n6. Pulmonary function: End-blood oxygen saturation ≥ 92% while breathing room air without supplemental oxygen. no clinically significant pleural effusion.\n\n9.Subjects and\u002For their partners of childbearing potential agree to use effective contraceptive measures throughout the entire treatment period and for 52 weeks after treatment, and during this period they must not donate eggs\u002Fsperm for assisted reproduction; Female participants of childbearing potential (women who have undergone sterilization surgery or have been postmenopausal for ≥12 months are not considered to have childbearing potential) must present a negative pregnancy test at screening and agree to use effective contraception throughout the study period.\n\n10.Willing to comply with all study procedures and voluntarily participate in this study and sign the informed consent form (ICF).\n\nKey Exclusion Criteria:\n\n1. Expected survival \\\u003C 3 months.\n2. Prior or concurrent active malignancy, with the exception of cured or recurrence-free for at least 3 years of cervical carcinoma in situ, non-invasive basal cell or squamous cell skin cancer, or locally advanced prostate cancer that has received curative treatment, or ductal carcinoma in situ after radical surgery.\n3. Prior use of CD70-targeted therapy.\n4. Previous treatment with CAR-T or any other genetically engineered cell therapy.\n5. History of central nervous system (CNS) disease or clinically significant CNS dysfunction, such as cerebral ischemia\u002Fhemorrhage, dementia, cerebellar disease, epilepsy, aphasia, dementia, etc.\n6. History of major organ transplantation (e.g., heart, lung, kidney, liver) or hematopoietic stem cell\u002Fbone marrow transplantation.\n7. Occurrence of myocardial infarction, cardiac angioplasty or stent implantation, unstable angina, or other clinically significant cardiac diseases within 12 months prior to screening.\n8. Presence of CNS metastasis or symptoms of CNS metastasis.\n9. Toxicities from prior therapy have not recovered to CTCAE grade ≤ 1, except for adverse events without safety risks (e.g., alopecia).\n10. The anti-tumor therapy received is still within 5 half-lives prior to the planned ET-970 infusion.\n11. Presence of uncontrolled active bacterial, fungal, or viral infections, or other infections deemed by the investigator as unsuitable for study participation.\n12. Positive for human immunodeficiency virus (HIV) antibody, positive for Treponema pallidum antibody, positive for hepatitis B surface antigen (HBsAg) or positive for hepatitis B core antibody (HBcAb) with detectable peripheral blood HBV DNA, positive for hepatitis C virus (HCV) antibody with detectable HCV RNA; except for infections that can be prevented or controlled with medication as judged by the investigator.\n13. History of other autoimmune diseases requiring immunosuppressive therapy.\n14. Known severe allergy to the study drug or any of its components.\n15. Pregnant or breastfeeding women.\n16. Use of any live vaccines against infectious disease within 6 weeks before lymphodepletion conditioning.\n17. Participation in another interventional clinical study and receipt of an active investigational drug within 3 months prior to signing the ICF, or intention to participate in another clinical trial or receive treatment for autoimmune diseases outside the protocol during the entire study period.\n18. Psychiatric disorders with depression or suicidal tendencies.\n19. Presence of any other medical condition that may affect the evaluation of the safety and efficacy of the study drug.\n20. Other factors due to which the patient is deemed unsuitable for participation by the investigator.","75 Years",{"count":58,"type":21},30,[24],"CLEAR CAR-T cell injection (ET-970) is an engineered CD70-targeting allogeneic Chimeric Antigen Receptor T-Cell (CAR-T cell). This is a multi-center, single-arm, open-label, early exploratory clinical study. The objective of this study is to evaluate the safety and preliminary efficacy of ET-970 in unresectable or metastatic clear cell renal cell carcinoma.",[62],"Unresectable or Metastatic Clear Cell Renal Cell Carcinoma","RECRUITING","2026-06-17",{"date":66,"type":40},"2026-06-22",{"date":68,"type":21},"2026-07-01",{"date":70,"type":21},"2028-03-31",{"name":46,"class":47},3,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":48},"100636760","thulium-laser-enucleation-with-bladder-neck-incision-for-small-volume-benign-prostatic-hyperplasia-100636760","NCT07569874","Thulium Laser Enucleation With Bladder Neck Incision for Small-Volume Benign Prostatic Hyperplasia","Thulium Laser Enucleation of the Prostate Combined With Bladder Neck Incision for Small-Volume Benign Prostatic Hyperplasia: A Multicentre, Randomized, Single-Blind, Controlled Trial","ThuLEP-BNI","Inclusion Criteria:\n\n* Male patients aged 40-80 years.\n* Diagnosis of benign prostatic hyperplasia (BPH) and scheduled to undergo surgical treatment.\n* International Prostate Symptom Score (IPSS) of at least 12, maximum urinary flow rate of no more than 15 mL\u002Fs, with a voided volume greater than 150 mL.\n* Prostate volume of less than 30 mL measured by transrectal ultrasound (TRUS), calculated as length × width × height × 0.52.\n* Ability, as assessed by the investigator, to understand the study requirements and complete the scheduled treatment, follow-up visits, and study-related assessments.\n\nExclusion Criteria:\n\n* Inability or refusal to provide written informed consent, or inability to comply with the required follow-up schedule.\n* Prostate-specific antigen (PSA) level of 10 ng\u002FmL or higher, unless prostate cancer has been excluded by biopsy.\n* Confirmed or suspected prostate or bladder malignancy.\n* Pre-existing bladder neck contracture or urethral stricture before surgery.\n* Known coagulation disorder or abnormal coagulation function.\n* Neurogenic bladder or detrusor underactivity that may affect bladder or urethral sphincter function.\n* Benign prostatic hyperplasia (BPH) complicated by acute urinary tract infection, acute prostatitis, or bacterial prostatitis.\n* History of prostate surgery, urethral stricture, or neurogenic bladder.\n* History of prostate cancer or pelvic radiotherapy.\n* Severe cardiovascular disease, pulmonary disease, or other systemic disease that, in the investigator's judgment, would make the patient unable to tolerate surgery.\n* Participation in another clinical trial related to benign prostatic hyperplasia (BPH) within 3 months before enrolment.\n* Any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in this study.","MALE","40 Years","80 Years",{"count":85,"type":21},615,[87],"NA","This study will evaluate the safety and effectiveness of thulium laser enucleation of the prostate combined with bladder neck incision in men with small-volume benign prostatic hyperplasia (BPH). Small-volume BPH may still cause significant bladder outlet obstruction and bothersome lower urinary tract symptoms, and the optimal surgical treatment for these patients remains uncertain.\n\nIn this multicenter, randomized, single-blind, controlled trial, 426 eligible men aged 40 to 80 years will be assigned in a 1:1:1 ratio to one of three groups: thulium laser enucleation of the prostate combined with bladder neck incision, thulium laser enucleation alone, or transurethral resection of the prostate. The main goal is to compare the incidence of bladder neck contracture at 6 months after surgery. Other outcomes include symptom improvement, urinary flow, pain score, sexual function, and safety outcomes during follow-up.",[90,91,92],"Benign Prostatic Hyperplasia","Bladder Outlet Obstruction","Lower Urinary Tract Symptoms (LUTS)",[94,95,96,97,98],"Small-Volume Benign Prostatic Hyperplasia","Thulium Laser Enucleation of the Prostate","Bladder Neck Incision","Bladder Neck Contracture","Lower Urinary Tract Symptoms","2026-06-16",{"date":101,"type":40},"2026-06-18",{"date":103,"type":21},"2026-07",{"date":105,"type":21},"2028-06",{"name":46,"class":47},{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":121,"leadSponsor":123,"locationsCount":48},"100642235","clinical-study-on-the-efficacy-and-safety-of-nalfurafine-hydrochloride-orally-disintegrating-tablets-in-treating-pruritus-in-patients-undergoing-maintenance-hemodialysis-100642235","NCT07650851","Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in Treating Pruritus in Patients Undergoing Maintenance Hemodialysis","Inclusion Criteria:\n\n* Age range of 18-80 years old (including both ends), male or female not limited.\n* Chronic renal failure patients who undergo stable dialysis for 3 months or more, receive regular hemodialysis 3 times a week, and are expected to have no significant changes in treatment or rapid changes in their condition during the clinical trial period.\n* Within one year prior to signing the informed consent form, the effectiveness of itch treatment (including topical medications such as moisturizers\u002Fmoisturizers, systemic medications such as antihistamines or antiepileptic drugs, and non pharmacological treatments) was not satisfactory.\n* Those who are able to understand and comply with the research procedures and methods, voluntarily participate in this study, and sign a written informed consent form.\n* The number of days during which VAS values are measured at both wake-up and bedtime in the baseline period must be no less than 5 days, and the average value of the larger VAS values in morning and evening measurements must not be less than 50 mm.\n* The number of days evaluated for the severity of itching in Xie Chuandao during the baseline period must be no less than 5 days at both wake-up and bedtime.\n\nExclusion Criteria:\n\n* Given poor compliance with dialysis treatment, researchers believe that it may affect the effectiveness and safety of clinical studies.\n* Patients who plan to undergo kidney transplantation or other elective surgeries during the study period.\n* Patients with alanine aminotransferase (ALT), aspartate aminotransferase (AST), or glutamine transferase (GGT) levels exceeding the upper limit of normal (ULN) by 2 times, or total bilirubin levels exceeding the upper limit of normal (ULN) by 2 times during the screening period.\n* Skin itching is not caused by chronic kidney disease, including allergic skin diseases (atopic dermatitis, urticaria, eczema, drug rash, etc.), physical skin diseases (prickly heat, solar rash, etc.), infectious skin diseases (insect bite dermatitis, chickenpox, measles, pyoderma, tinea corporis, etc.), cholestatic liver disease, etc.\n* Severe cardiovascular disease patients: those who have been screened for NYHA class III or IV, acute myocardial infarction, unstable angina, large pericardial effusion, severe arrhythmia, or abnormal electrocardiogram within the previous 6 months and are deemed unsuitable for inclusion by the researchers.\n* Screening for individuals who have been in the active stage of malignant tumors within the previous 12 months, or have received radiotherapy, chemotherapy, targeted therapy, and immunotherapy during this period.\n* There are uncontrollable or drug-induced fungal, bacterial, viral, or other infections, including tuberculosis patients undergoing anti tuberculosis treatment, patients known to be infected with human immunodeficiency virus (HIV), etc.\n* Hypertensive patients who cannot achieve good control with drug therapy: systolic blood pressure ≥ 180mmHg, or diastolic blood pressure ≥ 110mmHg.\n* Patients who are currently using glucocorticoids and immunosuppressants.\n* Patients with mental illness or cognitive impairment who are unable to correctly understand VAS scores and describe their own feelings.\n* Received or adjusted antihistamines, systemic or local corticosteroids (excluding ear or eye preparations), calcineurin inhibitors, gabapentin, pregabalin, and other restricted combination drugs within 7 days prior to screening, or expected to change their treatment regimen during the study period.\n* Started receiving or adjusting drugs that may affect the assessment of itch relief efficacy within 2 weeks prior to screening, including but not limited to antipsychotics, sedatives, selective serotonin reuptake inhibitors (SSRIs), anxiolytics, or tricyclic antidepressants, or expected to change their treatment regimen during the study period.\n* Individuals with a history of drug abuse, drug dependence, or alcohol abuse within the past 12 months prior to screening.\n* Select patients who have received phototherapy for pruritus within the previous month.\n* Individuals who have used opioid receptor agonists or antagonists within the past 2 weeks prior to screening.\n* Individuals with a known history of allergy to opioid drugs, or those who are allergic to test drug excipients.\n* Individuals who have participated in other clinical studies and used the investigational drug or medical device within the 28 days prior to screening, or whose investigational drug is within 5 half lives prior to screening.\n* Pregnant women, breastfeeding women, patients with positive pregnancy tests, or those who do not agree to use contraception during the study period.\n* Other patients deemed unsuitable by researchers to participate in this clinical study.",{"count":5,"type":21},[87],"This is a randomized, open-label, multi-center clinical study aimed at evaluating the efficacy and safety of 12 weeks of nalfurafine hydrochloride administration in the treatment of pruritus in patients undergoing maintenance hemodialysis.",[117],"Chronic Kidney Disease-Associated Pruritus in Hemodialysis","2026-06-14",{"date":99,"type":40},{"date":68,"type":21},{"date":122,"type":21},"2028-12-31",{"name":46,"class":47},{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":17,"minAge":131,"maxAge":56,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":136,"conditions":137,"keywords":140,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":48},"100632534","phase-2-venetoclax-azacitidine-in-combination-with-chidamide-and-cag-in-fit-older-patients-with-acute-myeloid-leukaemia-100632534","NCT07514936","Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia","Venetoclax-Azacitidine in Combination With Chidamide and CAG Versus Daunorubicin and Cytarabine in Fit Older Patients With Acute Myeloid Leukaemia：A Multicenter, Randomized, Controlled, Phase 3 Trial","Inclusion Criteria:\n\n1. Voluntary participation in the clinical study; the subject or legal guardian fully understands and is informed about the study and has signed the Informed Consent Form (ICF); willing to follow and able to complete all trial procedures;\n2. Age between 60-75 years at the time of screening, with no gender restrictions;\n3. Patients are newly diagnosed with AML, and the diagnosis conforms to the standards of the Chinese Medical Association 2021 edition;\n4. No severe allergic constitution;\n5. Liver function: ALT and AST \\\u003C= 2.5 times the upper limit of normal values, bilirubin \\\u003C= 2 times the upper limit of normal values;\n6. Renal function: creatinine \\\u003C= upper limit of normal values;\n7. No uncontrollable infections or severe mental illnesses;\n8. Performance status score is 0-3 (ECOG), with an expected survival of at least 4 months.\n\nExclusion Criteria:\n\n1. Patients who are allergic to the study medication or have contraindications to it;\n2. Pregnant or breastfeeding women;\n3. Patients with active infections;\n4. Patients with long-term smoking or alcohol abuse that could affect the evaluation of trial results;\n5. Patients with mental disorders or other conditions that prevent obtaining informed consent, or who are unable to cooperate with the treatment and examination procedures;\n6. Patients who have undergone major organ surgery within the last 6 weeks;\n7. Abnormal liver function, with total bilirubin \\> 1.5 times the upper limit of normal, ALT\u002FAST \\> 2.5 times the upper limit of normal, or liver-infiltrated patients with ALT\u002FAST \\> 5 times the upper limit of normal; abnormal renal function, with serum creatinine \\> 1.5 times the upper limit of normal;\n8. Patients whom the investigator deems unsuitable for this clinical trial (e.g., poor compliance, drug abuse, etc.).","60 Years",{"count":133,"type":21},120,[135],"PHASE2","This study is a multicenter, prospective, randomized, controlled clinical trial, observing the efficacy and safety of the CACAG+Venetoclax regimen (Chidamide + Azacitidine + Aclarubicin + Cytarabine + Recombinant Human Granulocyte Colony-Stimulating Factor + Venetoclax) in elderly patients with newly diagnosed Acute Myeloid Leukemia (AML). The control group applies the standard \"3+7\" regimen. The aim is to improve the remission rate of AML patients, reduce the probability of adverse events, and thereby improve patient prognosis and extend patient survival.",[138,139],"Newly Diagnosed Acute Myeloid Leukemia (AML)","Elderly Patients",[139,141,142],"newly diagnosed","Acute Myeloid Leukemia","2026-06-11",{"date":145,"type":40},"2026-06-15",{"date":147,"type":40},"2024-11-18",{"date":149,"type":21},"2027-12-31",{"name":46,"class":47},{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":170,"leadSponsor":172,"locationsCount":48},"100636813","phase-1-clinical-study-of-the-safety-and-efficacy-of-allogeneic-tcr-enhanced-v2-t-cell-in-patients-with-malignant-tumors-100636813","NCT07570563","Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors.","A Clinical Study on the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell Injection in the Treatment of Patients With Malignant Tumors","Inclusion Criteria:\n\n* Age 18-75 (inclusive).\n* Expected survival time ≥ 3 months.\n* Meets current clinical diagnostic criteria with a confirmed diagnosis of a malignant hematologic tumor or solid tumor, and has failed standard therapy (for solid tumors, at least one evaluable lesion according to RECIST v1.1 is required).\n* Adequate bone marrow reserve and essentially normal liver and kidney function (laboratory tests must meet the following criteria prior to the first allogeneic TCR-enhanced Vδ2 T cell treatment):\n* Hematology: White Blood Cell Count (WBC) ≥ 2.5×10⁹\u002FL, Lymphocyte Count (LY) ≥ 0.8×10⁹\u002FL, Hemoglobin (Hb) ≥ 80 g\u002FL, Platelets (PLT) ≥ 75×10⁹\u002FL.\n* Liver: ALT ≤ 3 × ULN; AST ≤ 3 × ULN; Total Bilirubin ≤ 3.0 × ULN.\n* Kidney: Serum Creatinine ≤ 1.5 × ULN.\n* Cardiac: Left Ventricular Ejection Fraction (LVEF) ≥ 50% as measured by echocardiogram.\n* Pulmonary: Normal oxygen saturation without supplemental oxygen.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-1.\n* A negative pregnancy test is required for women of childbearing potential. Both male and female subjects must agree to use effective contraception during the treatment period and for 1 year thereafter.\n* Able to understand the trial requirements and is willing to participate in the clinical study as required.\n* Voluntarily signs the informed consent form for the clinical trial.\n\nExclusion Criteria:\n\n* Known history of allergy, hypersensitivity, intolerance, or contraindication to allogeneic TCR-enhanced Vδ2 T cell or any components of the study drugs (including fludarabine, cyclophosphamide and albumin paclitaxel).\n* Continuous use of immunosuppressants within 1 month prior to allogeneic TCR-enhanced Vδ2 T cell infusion.\n* History of cerebrovascular accident or seizure within 6 months prior to signing the informed consent.\n* Symptomatic brain metastases.\n* Known psychiatric or substance abuse disorders that would compromise compliance with study requirements.\n* Positive for Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb) with detectable Hepatitis B virus (HBV) DNA levels outside the normal reference range; positive for Hepatitis C virus (HCV) antibody with detectable HCV RNA; positive for Human Immunodeficiency Virus (HIV) antibody; positive for syphilis.\n* Severe cardiac disease, including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (NYHA Class ≥ III), and severe arrhythmia.\n* Active or uncontrolled infection requiring systemic therapy (except for mild urogenital and upper respiratory tract infections).\n* Has not recovered from acute toxic effects of prior therapy (i.e., persisting hematological or organ toxicity ≥ Grade 2 related to prior therapy, excluding abnormalities associated with the study disease and its history).\n* Diagnosed with immunodeficiency.\n* Active infection requiring systemic treatment.\n* Female subjects of childbearing potential planning pregnancy within 2 years after cell infusion; or male subjects whose partners are planning pregnancy within 2 years after cell infusion.\n* Participation in another investigational drug clinical study within 1 month prior to screening.\n* Last anti-tumor therapy administered less than 5 half-lives of the drug prior to planned allogeneic TCR-enhanced Vδ2 T cell infusion.\n* Any other condition deemed by the investigator to make the subject unsuitable for participation in this study.",{"count":159,"type":21},24,[161,135],"PHASE1","The allogeneic TCR-enhanced Vδ2 T cell product is a novel genetically engineered cellular therapeutic. By engineering a specific BTN protein-binding moiety on its cell surface, this product harnesses the intrinsic tumoricidal potential of endogenous Vδ2 T cells and augments BTN protein recognition capability, thereby significantly boosting tumor cell killing potency. Notably, this engineered cell product exhibits no expression of co-stimulatory signaling domains and CD3ζ domains. This design circumvents T cell exhaustion triggered by overactivation and markedly enhances the in vivo persistence of therapeutic cells.\n\nThis is an open, prospective, open-label Phase I\u002FII clinical trial designed to assess the safety and therapeutic efficacy of allogeneic TCR-enhanced Vδ2 T cell injection in patients with relapsed or refractory hematologic malignancies and advanced solid tumors.",[164,165],"Hematologic Malignancy","Solid Tumor","2026-06-05",{"date":168,"type":40},"2026-06-08",{"date":166,"type":40},{"date":171,"type":21},"2031-12-31",{"name":46,"class":47},{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":48},"100643740","phase-1-human-placenta-derived-3d-mesenchymal-stem-cellsguojianqingke-100643740","NCT07635758","Human Placenta-derived 3D Mesenchymal Stem Cells(Guojianqingke)","A Phase I\u002FIIa Clinical Trial on the Safety, Tolerability, and Preliminary Efficacy of Human Placental-Derived 3D Mesenchymal Stem Cell Injection Administered Via the Intravenous Route in Patients With Acute Ischemic Stroke (AIS): A Randomized, Double-Blind, Placebo-Controlled Study","3D MSC - QK01","Inclusion Criteria:\n\n1. Age ≥18 years and ≤80 years; any gender\n2. Body weight 45-90 kg\n3. Diagnosed with acute ischemic stroke, with onset between 6 and 72 hours (inclusive) prior to enrollment; received thrombolysis or not planned for thrombolysis and no planned thrombectomy\n4. NIHSS score 6-20, with NIHSS item 1a (Level of Consciousness) \\\u003C2\n5. Participant or legally authorized representative able to understand and provide written informed consent\n\nExclusion Criteria:\n\n1. Significant pre-stroke disability (pre-stroke modified Rankin Scale \\[mRS\\] score ≥2)；\n2. History of intracerebral hemorrhage, subarachnoid hemorrhage, or hemorrhagic transformation after this ischemic stroke (imaging re-evaluation before planned dosing shows new bleeding within the infarct area accompanied by neurological deterioration \\[e.g., NIHSS total score increased ≥4 points from admission\\], judged by the investigator as unsuitable for clinical trial participation); or presence of cerebrovascular malformation, multiple sclerosis, severe traumatic brain injury history, encephalitis, or other conditions causing stroke-like symptoms\n3. Uncontrolled systemic diseases, including but not limited to: hypertension (systolic BP \\>180 mmHg and\u002For diastolic BP ≥120 mmHg), diabetes (diabetic acute complications such as ketoacidosis, hyperosmolar hyperglycemic state, lactic acidosis, or hypoglycemic coma within 3 months, or difficult-to-control diabetes \\[blood glucose \\>16.8 mmol\u002FL or \\\u003C2.8 mmol\u002FL\\]), renal disease (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²), hepatic failure (Child-Pugh Class C), severe heart failure (NYHA Class IV), severe chronic respiratory disease\n4. History of seizure (except secondary epilepsy not currently requiring drug treatment)\n5. History of brain tumor or malignancy within the past 5 years, including concurrent second primary malignancy, except: a) radically excised non-melanoma skin cancer; b) radically treated cervical carcinoma in situ; c) radically treated papillary thyroid carcinoma; d) radically treated localized prostate cancer; e) radically treated ductal carcinoma in situ of the breast\n6. History of any of the following:\n\n   1. Active or uncontrolled autoimmune disease (e.g., antiphospholipid antibody syndrome)\n   2. Protein C or protein S deficiency\n   3. Sickle cell anemia\n   4. Deep vein thrombosis\n   5. Pulmonary embolism\n   6. Cerebrovascular malformation (e.g., moyamoya disease)\n7. Any concomitant disease or physical condition (e.g., severe arthritis, amputation, blindness, severe disability from prior stroke) that, in the investigator's judgment, would significantly interfere with accurate assessment of mRS, NIHSS, or BI scores\n8. Major surgery within the past 30 days (e.g., thoracotomy, cardiac surgery, abdominal surgery, intracranial surgery)\n9. Currently severe illness, including:\n\n   1. Severe heart failure (NYHA Class III-IV)\n   2. Severe febrile illness (any fever within 14 days before dosing requiring systemic anti-infective treatment)\n   3. Primary or secondary immunodeficiency disease, or long-term or recent high-dose immunosuppressant or systemic corticosteroid therapy before screening\n   4. Hemorrhagic disorder or bone marrow transplantation\n   5. Any comorbidity that the investigator believes may shorten survival or limit ability to complete the study\n   6. Uncontrolled depression affecting daily life before stroke, dementia that may affect clinical assessment, or other neurological or psychiatric disorders that the investigator believes may affect study assessment\n10. Uncontrolled active infection; or systemic anti-infective treatment within 7 days before dosing that the investigator assesses may shortly convert to uncontrolled active infection\n11. Organ function meeting any of the following:\n\n    Hematology:\n\n    Absolute neutrophil count (ANC) \\\u003C1.0×10⁹\u002FL Platelets (PLT) \\\u003C75×10⁹\u002FL Hemoglobin (Hb) \\\u003C80 g\u002FL\n\n    Hepatic\u002FRenal Function:\n\n    Alanine aminotransferase (ALT) \\>2.5×ULN Aspartate aminotransferase (AST) \\>2.5×ULN Total bilirubin (TBIL) \\>1.5×ULN Creatinine \\>1.5×ULN\n\n    Coagulation:\n\n    Phase I: Not receiving anticoagulant or antithrombotic therapy: PT and APTT \\>1.25×ULN, INR \\>1.4; Receiving anticoagulant or antithrombotic therapy: PT and APTT \\>1.5×ULN, INR \\>3.0 Phase IIa: Not receiving anticoagulant therapy: APTT \\>2.0×ULN or PT \\>2.0×ULN; Receiving anticoagulant therapy: judged by investigator to have severe bleeding risk\n12. Clinically significant uncorrected electrolyte disturbances (e.g., hyperkalemia, hypernatremia) that the investigator believes may affect study assessment\n13. Unable to undergo head CT\u002FMRI for any reason (e.g., cardiac pacemaker, metal implants, claustrophobia)\n14. History of drug abuse or alcohol abuse within the past year\n15. Allergy to bovine or porcine products, human serum albumin products, or known allergy to gentamicin\n16. Participation in another investigational drug, device study, or stem cell\u002Fimmune cell therapy within 3 months before treatment\n17. History of blood transfusion or vaccination with attenuated\u002Flive vaccine within 3 months before screening\n18. Pregnant or lactating women; or participants with pregnancy plans during the study period, or unwilling to use effective contraception; or females of childbearing potential with positive pregnancy test; or female participants on long-term oral contraceptives (continuous use \\>30 days)\n19. Other reasons deemed by the investigator as unsuitable for participation or inability to complete study procedures (e.g., lack of willingness)",{"count":159,"type":21},[161,135],"This is a Phase I\u002FIIa clinical trial evaluating human placental-derived 3D mesenchymal stem cell (MSC) injection in patients with acute ischemic stroke (AIS). Phase I is a single-dose escalation study to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D). Phase IIa explores preliminary efficacy. Each participant undergoes screening (up to 72 hours before treatment), a single-day treatment period, and follow-up for up to 720 days (24 months).",[185],"Acute Ischemic Stroke",[187,188],"Acute Ischemic Stroke，AIS","mesenchymal stem cells","2026-06-03",{"date":191,"type":40},"2026-06-09",{"date":193,"type":40},"2026-06-01",{"date":195,"type":21},"2028-12",{"name":46,"class":47},{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":213,"leadSponsor":215,"locationsCount":48},"100637916","phase-1-safety-and-efficacy-of-ksvcbd-injection-in-b-cell-non-hodgkins-lymphoma-expressing-cd19-andor-bcma-100637916","NCT07620314","Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and\u002For BCMA","A Clinical Study on the Safety and Efficacy of KSVCBD Injection in the Treatment of B-cell Non-Hodgkin's Lymphoma With Positive Expression of CD19 and\u002For BCMA","Key Inclusion Criteria:\n\n1. Age 18-75 years (inclusive), any gender.\n2. Subjects must meet the following diagnostic and treatment criteria:\n\n   2.1Histologically or cytologically confirmed B-NHL (according to the 2016 WHO classification of lymphoid neoplasms):\n   * Diffuse large B-cell lymphoma, not otherwise specified.\n   * Primary mediastinal large B-cell lymphoma.\n   * Diffuse large B-cell lymphoma transformed from follicular lymphoma (TFL).\n   * High-grade B-cell lymphoma with MYC and BCL2 and\u002For BCL6 rearrangements.\n   * Follicular lymphoma (FL).\n   * High-grade B-cell lymphoma, not otherwise specified.\n   * Mantle cell lymphoma (pathologically confirmed, with monoclonal B cells carrying t(11.14) and\u002For overexpressing cyclin D1).\n   * Marginal zone lymphoma (including nodal or splenic marginal zone B-cell lymphoma and mucosa-associated lymphoid tissue \\[MALT\\] lymphoma).\n\n   2.2Subjects must be in a relapsed or refractory state during the screening period:\n   * Definition of relapse: Disease progression (PD) after achieving remission (including PR or CR) following at least one standard treatment regimen (must include rituximab).\n   * Definition of refractory: Must meet any of the following criteria:\n\n   Best response of stable disease (SD) or PD after at least 4 cycles of first-line standard treatment (e.g., 4 cycles of R-CHOP).\n\n   Achieved remission after at least 6 cycles of first-line standard treatment but experienced PD within 6 months.\n\n   Best response of PD after first-line standard treatment. Relapse (must be biopsy-proven) or PD within 12 months after autologous stem cell transplantation (ASCT). if salvage therapy was received, no response (SD or PD) to the last line of treatment.\n   * For TFL, subjects must have received adequate prior treatment for follicular lymphoma, at least one line of treatment for TFL after transformation, and be relapsed or refractory after the last line of treatment.\n   * For mantle cell lymphoma, prior treatment must include anthracycline- or bendamustine-containing chemotherapy, anti-CD20 therapy (except for CD20-negative cases), and BTK inhibitor therapy.\n   * For indolent lymphomas (grade 1-3a FL and marginal zone lymphoma), subjects must have received at least two prior lines of therapy.\n   * For other types, prior treatment must include anti-CD20 therapy (except for CD20-negative cases) and anthracycline-containing chemotherapy.\n\n   2.3Subjects judged by the investigator to be intolerant to standard therapy may also be included in the study.\n3. Intranodal lesion with long-axis diameter \\> 1.5 cm, or extranodal lesion with long-axis diameter \\> 1.0 cm (according to the 2014 Lugano response criteria).\n4. Positive expression of CD19 and\u002For BCMA in tumor tissue confirmed by flow cytometry and\u002For histopathology (previous pathology or flow cytometry diagnosis of CD19 and\u002For BCMA in the patient, as confirmed by the investigator, is acceptable). For subjects who have previously received anti-CD19 and\u002For anti-BCMA therapy, a tumor biopsy should be performed to confirm current positive expression of CD19 and\u002For BCMA.\n5. Toxicities from any prior therapy must be stable and have resolved to ≤ Grade 1 (excluding hematologic toxicities and clinically insignificant toxicities such as alopecia).\n6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n\nKey Exclusion Criteria:\n\n1. Expected survival \\\u003C 3 months.\n2. History of or concurrent active malignancy. Exceptions include: carcinoma in situ of the cervix that has been cured or with no recurrence for at least 3 years, non-invasive basal cell or squamous cell skin cancer, locally advanced prostate cancer that has received curative treatment, or ductal carcinoma in situ after radical surgery.\n3. Prior allogeneic hematopoietic stem cell transplantation (allo-HSCT) or autologous HSCT within 3 months prior to KSVCBD infusion.\n4. Solitary extramedullary soft tissue plasmacytoma.\n5. Diagnosis of plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome, or primary AL amyloidosis.\n6. Presence of CNS metastasis or symptoms of CNS metastasis.\n7. Receipt of anti-tumor therapy that is still within 5 half-lives prior to the planned KSVCBD infusion.\n8. Presence of uncontrolled active infections.\n9. Positive for human immunodeficiency virus (HIV) antibody, positive for Treponema pallidum antibody, positive for hepatitis B surface antigen (HBsAg) or positive for hepatitis B core antibody (HBcAb) with detectable peripheral blood HBV DNA, or positive for hepatitis C virus (HCV) antibody with detectable HCV RNA. except for infections that the investigator judges can be prevented or controlled with medication.\n10. Known active autoimmune disease requiring systemic treatment.\n11. Known severe allergy to the study drug or any of its components.\n12. Pregnant or breastfeeding women.\n13. Receipt of a live vaccine within 6 weeks prior to enrollment.",{"count":20,"type":21},[161],"KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This multicenter, single-arm, open-label, early exploratory clinical study is designed to evaluate the preliminary safety and efficacy of KSVCBD injection in patients with relapsed or refractory (r\u002Fr) B-cell non-Hodgkin's lymphoma (NHL) CD19 and\u002For BCMA.",[208],"Non-Hodgkin's Lymphoma","2026-05-27",{"date":211,"type":40},"2026-06-02",{"date":145,"type":21},{"date":214,"type":21},"2029-03-30",{"name":46,"class":47},{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":72},"100639986","phase-1-safety-and-efficacy-of-ksvcbd-injection-in-multiple-myeloma-expressing-cd19-andor-bcma-100639986","NCT07620275","Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and\u002For BCMA","A Multicenter Clinical Study on the Safety and Efficacy of KSVCBD Injection in the Treatment of Multiple Myeloma With Positive Expression of CD19 and\u002For BCMA","Key Inclusion Criteria:\n\n1. Age 18-75 years (inclusive), any gender.\n2. Subjects must meet the following diagnostic and treatment criteria:\n\n   2.1 According to the IMWG 2014 diagnostic criteria, subjects must have a confirmed diagnosis of multiple myeloma and be in a relapsed or refractory state at screening, while meeting all of the following conditions:\n   * Must have received at least 3 prior lines of MM therapy (including a proteasome inhibitor and an immunomodulatory agent). consecutive cycles of induction chemotherapy, hematopoietic stem cell transplantation, and maintenance therapy are considered as one line of therapy if no disease progression occurs between these treatments. each line of therapy must consist of at least one complete treatment cycle, unless the best response to that regimen was disease progression.\n   * Must have experienced disease progression during or within 12 months after the most recent anti-myeloma therapy. or the subject must have experienced disease progression within the last 6 months and subsequently shown no response to the most recent line of therapy. Lack of response is defined as failure to achieve at least a minimal response (MR) or experiencing disease progression (PD) during treatment.\n\n   2.2 Subjects judged by the investigator to be intolerant to standard therapy may also be included in the study.\n3. Presence of measurable lesions at screening as determined by any of the following criteria:\n\n   * Serum monoclonal paraprotein (M-protein) level ≥ 1.0 g\u002FdL, or urinary M-protein level ≥ 200 mg\u002F24 hours. or\n   * For light chain multiple myeloma without measurable lesions in serum or urine: serum immunoglobulin free light chain level ≥ 10 mg\u002FdL and an abnormal serum immunoglobulin κ\u002Fλ free light chain ratio.\n4. Positive expression of CD19 and\u002For BCMA in tumor tissue confirmed by flow cytometry and\u002For histopathology (previous pathology or flow cytometry diagnosis of CD19 and\u002For BCMA in the patient, as confirmed by the investigator, is acceptable). For subjects who have previously received anti-CD19 and\u002For anti-BCMA therapy, a tumor biopsy should be performed to confirm current positive expression of CD19 and\u002For BCMA.\n5. Toxicities from any prior therapy must be stable and have resolved to ≤ Grade 1 (excluding hematologic toxicities and clinically insignificant toxicities such as alopecia).\n6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n\nKey Exclusion Criteria:\n\n1. Expected survival \\\u003C 3 months.\n2. History of or concurrent active malignancy. Exceptions include: carcinoma in situ of the cervix that has been cured or with no recurrence for at least 3 years, non-invasive basal cell or squamous cell skin cancer, locally advanced prostate cancer that has received curative treatment, or ductal carcinoma in situ after radical surgery.\n3. Prior allogeneic hematopoietic stem cell transplantation (allo-HSCT) or autologous HSCT within 3 months prior to KSVCBD infusion.\n4. Solitary extramedullary soft tissue plasmacytoma.\n5. Diagnosis of plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome, or primary AL amyloidosis.\n6. Presence of CNS metastasis or symptoms of CNS metastasis.\n7. Receipt of anti-tumor therapy that is still within 5 half-lives prior to the planned KSVCBD infusion.\n8. Presence of uncontrolled active infections.\n9. Positive for human immunodeficiency virus (HIV) antibody, positive for Treponema pallidum antibody, positive for hepatitis B surface antigen (HBsAg) or positive for hepatitis B core antibody (HBcAb) with detectable peripheral blood HBV DNA, or positive for hepatitis C virus (HCV) antibody with detectable HCV RNA. except for infections that the investigator judges can be prevented or controlled with medication.\n10. Known active autoimmune disease requiring systemic treatment.\n11. Known severe allergy to the study drug or any of its components.\n12. Pregnant or breastfeeding women.\n13. Receipt of a live vaccine within 6 weeks prior to enrollment.",{"count":20,"type":21},[161],"KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This multicenter, single-arm, open-label, early exploratory clinical study is designed to evaluate the preliminary safety and efficacy of KSVCBD injection in patients with relapsed or refractory (r\u002Fr) multiple myeloma(MM) expressing CD19 and\u002For BCMA.",[227],"Multiple Myeloma",{"date":211,"type":40},{"date":230,"type":21},"2026-06-10",{"date":232,"type":21},"2029-03-15",{"name":46,"class":47},{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":244,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":254,"leadSponsor":256,"locationsCount":48},"100637490","early-phase-1-safety-and-efficacy-of-ksvcbd-injection-in-autoimmune-diseases-100637490","NCT07613411","Safety and Efficacy of KSVCBD Injection in Autoimmune Diseases","A Clinical Study to Evaluate the Safety and Efficacy of KSVCBD Injection in Patients With Autoimmune Diseases","Inclusion Criteria:\n\n1. Age 18-65 years (inclusive), any gender.\n2. Subjects diagnosed with the following autoimmune disease: moderate\u002Fsevere refractory Systemic Lupus Erythematosus, elapsed\u002Frefractory Systemic Sclerosis, relapsed\u002Frefractory ANCA-Associated Vasculitis, refractory Idiopathic Inflammatory Myopathy, active Sjögren's Syndrome, chronic\u002Frefractory Immune Thrombocytopenia, refractory Antiphospholipid Syndrome, relapsed\u002Frefractory pemphigus, relapsed\u002Frefractory IgG4-Related Disease.\n3. Having adequate organ function as required by the protocol.:\n4. Voluntarily adhere to the contraception requirements as specified in the protocol.\n5. Willing to comply with all study procedures and voluntarily participate in this study and sign the informed consent form (ICF).\n\nExclusion Criteria:\n\n1. Previous or current active malignancy, including patients with cancer-associated polymyositis\u002Fdermatomyositis. Exceptions are cured or relapse-free for at least 3 years: cervical carcinoma in situ, non-invasive basal cell or squamous cell skin cancer, locally advanced prostate cancer after radical treatment, or ductal carcinoma in situ after radical surgery.\n2. Severe pulmonary disease within the past 1 year, such as moderate\u002Fsevere pulmonary arterial hypertension (pulmonary artery systolic pressure \\>50 mmHg on echocardiography), requirement for oxygen therapy via reservoir mask or non-invasive\u002Finvasive ventilator support at screening.\n3. Use of any of the protocol specified drugs or treatments within the specified timeframes.\n4. History or current symptoms of severe central nervous system (CNS) disease within the past 6 months.\n5. Known severe allergy to the study drug or any of its components.\n6. Presence of uncontrolled fungal, bacterial, or viral infection, or other infections considered by the investigator to make the subject unsuitable for participation.\n7. History of major organ transplant or hematopoietic stem cell\u002Fbone marrow transplantation.\n8. History of other autoimmune diseases requiring systemic treatment, other than the target indication.\n9. History of non-IIM conditions such as drug induced myopathy, HIV associated myopathy, thyroid myopathy, or family history of myopathy.\n10. Pregnant or breastfeeding women.\n11. Use of any live vaccines within 6 weeks before enrollment.\n12. Participation in another interventional clinical study and receipt of an active investigational drug within 3 months prior to signing the ICF, or intention to participate in another clinical trial or receive treatment for autoimmune diseases outside the protocol during the entire study period.\n13. Psychiatric disorders with depression or suicidal tendencies.\n14. Any other factors considered by the investigator to make the subject unsuitable for enrollment or to affect the subject's participation or completion of the study.","65 Years",{"count":243,"type":21},60,[24],"KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This single-arm, open-label, early exploratory clinical study is designed to evaluate the safety and preliminary efficacy of KSVCBD injection in patients with Autoimmune Diseases.",[247],"Autoimmune Diseases",[247,249],"Immunotherapy","2026-05-22",{"date":252,"type":40},"2026-05-29",{"date":193,"type":21},{"date":255,"type":21},"2029-03-31",{"name":46,"class":47},{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":264,"enrollmentInfo":265,"targetDuration":4,"studyType":22,"phases":267,"briefSummary":268,"conditions":269,"keywords":271,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":278,"leadSponsor":280,"locationsCount":281},"100637274","early-phase-1-yiqi-huoxue-jiedu-formula-combined-with-bacteriophages-in-the-treatment-of-severe-pneumonia-100637274","NCT07612605","Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia","A Randomized Controlled Trial (RCT) of Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia Caused by Drug-resistant Gram-negative Bacilli","Inclusion Criteria:\n\n* Patients who meet the diagnostic criteria for severe pneumonia caused by drug-resistant Gram-negative bacilli and conform to the TCM syndrome differentiation of Qi deficiency, toxin accumulation and blood stasis syndrome;\n* Patients confirmed by rapid on-site microbiological evaluation (M-ROSE), clinical microbial culture and drug susceptibility testing (based on the drug susceptibility test results of our hospital or other Grade A tertiary hospitals) to be infected with multidrug-resistant Klebsiella pneumoniae, Acinetobacter baumannii or Pseudomonas aeruginosa;\n* Aged 18 to 85 years old;\n* Patients or their family members agree to cooperate with the collection of upper and lower respiratory tract specimens, consent to bronchoscopy plus bronchoalveolar lavage, and agree to receive nebulized inhalation of bacteriophage therapy;\n* Patients or their family members have fully read, understood and signed the informed consent form.\n\nExclusion Criteria:\n\n* Women who are pregnant or lactating;\n* Patients with immunodeficiency;\n* Patients receiving immunosuppressive therapy or suffering from immunodeficiency diseases;\n* Patients who have received mechanical ventilation for more than 60 days prior to enrollment;\n* Patients with active pulmonary tuberculosis, lung abscess, or Grade D chronic obstructive pulmonary disease (COPD);\n* Patients with incomplete sampling or clinical data;\n* Patients with known allergies to bacteriophage products or the components of Yiqi Huoxue Jiedu Formula;\n* Patients judged by the researchers as unsuitable for participation in this study.","85 Years",{"count":266,"type":21},250,[24],"Through a prospective randomized controlled trial, we systematically evaluate the effects of Yiqi Huoxue Jiedu Formula combined with bacteriophage therapy on the bacterial clearance rate, disease improvement rate and mortality rate in patients with severe pneumonia caused by drug-resistant bacteria, so as to clarify its clinical transformation value.",[270],"Pneumonia",[272,273,274,270],"bacteriophage","Yiqi Huoxue Jiedu Formula","drug-resistant bacteria","2026-05-21",{"date":252,"type":40},{"date":193,"type":21},{"date":279,"type":21},"2029-12-31",{"name":46,"class":47},4,{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":288,"sex":17,"minAge":131,"maxAge":289,"enrollmentInfo":290,"targetDuration":292,"studyType":293,"phases":4,"briefSummary":294,"conditions":295,"keywords":297,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":303,"startDateStruct":304,"completionDateStruct":305,"leadSponsor":306,"locationsCount":4},"100637745","prediction-of-age-related-hearing-loss-based-on-comprehensive-risk-factors-100637745","NCT07612618","Prediction of Age-Related Hearing Loss Based on Comprehensive Risk Factors","Inclusion Criteria:\n\n1. Age ≥ 60 years;\n2. Availability of longitudinal pure-tone audiometry data;\n3. Documented history of occupational noise exposure;\n4. Complete clinical data (including past medical history and medication history).\n\nExclusion Criteria:\n\n1. Hearing loss caused by non-age or non-noise factors (e.g., otitis media, otosclerosis, Meniere's disease);\n2. Missing clinical data \\>20%;\n3. Concurrent severe mental illness or cognitive impairment (unable to complete audiological assessment).",true,"100 Years",{"count":291,"type":21},1000,"1 Year","OBSERVATIONAL","This study aims to develop a predictive model for age-related hearing loss (ARHL) based on multi-source risk factors and artificial intelligence techniques. A retrospective analysis will be conducted on 1,000 cases with 15-year longitudinal clinical data, including audiological assessments and noise exposure history. Machine learning algorithms will be employed to construct a predictive model for hearing loss progression. Additionally, a prospective cohort of 100 community-dwelling elderly individuals will be enrolled. Blood samples will be collected for low-abundance targeted proteomics analysis to screen for biomarkers associated with cognitive impairment. This study will establish an early risk identification tool for ARHL and propose strategies for the screening and prevention of dementia in individuals with hearing impairment, thereby providing evidence-based support for early intervention in auditory and cognitive health in the elderly.",[296],"Age-related Hearing Loss",[298,299,300,301,302],"Age-related hearing loss","prediction model","machine learning","proteomics","cognitive impairment",{"date":252,"type":40},{"date":193,"type":21},{"date":149,"type":21},{"name":46,"class":47},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":288,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":293,"phases":4,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":329,"locationsCount":48},"100638611","management-of-age-related-auditory-decline-and-early-warning-of-its-co-occurring-dementia-100638611","NCT07608640","Management of Age-Related Auditory Decline and Early Warning of Its Co-occurring Dementia","AHEAD","Inclusion Criteria:\n\n1. Aged 60 years or older.\n2. Clear consciousness and able to cooperate with all study assessments and examinations.\n3. Permanent local residents who have lived in the area for at least 9 months per year and are willing to complete long-term follow-up.\n\nlong-term follow-up：\n\n1. Diagnosis of sensorineural hearing loss.\n2. Bilaterally symmetric hearing with air conduction threshold difference ≤15 dB at 0.5 kHz, 1 kHz, 2 kHz and 4 kHz between two ears.\n3. Hearing loss not caused by non-age-related factors.\n\nExclusion Criteria:\n\n1. Unable to complete pure-tone audiometry and other auditory examinations. History of central nervous system diseases, including Parkinson's disease, stroke, intracranial tumor or brain trauma.\n2. Severe uncontrolled systemic diseases (cardiac, pulmonary, hepatic, renal insufficiency) or advanced malignant tumor with expected survival less than 3 years.\n3. Any other condition judged by the investigator inappropriate for study enrollment.",{"count":315,"type":21},3000,"Against the backdrop of global population aging, age-related hearing loss (ARHL) has reached epidemic proportions and is increasingly recognized as an independent risk factor for cognitive decline and other major neurodegenerative diseases. This study aims to systematically develop an integrated framework for the early warning, precise assessment, and intervention management of ARHL.\n\nUsing a national multicenter design, the project will establish a prospective cohort of more than 3,000 older adults. We will integrate multimodal data including audiological tests, cognitive function assessments, and blood biomarkers, and employ artificial intelligence and unsupervised machine learning methods to address critical bottlenecks in the field: the unclear mechanistic link between ARHL and cognitive decline, and the lack of validated predictive tools.\n\nSpecifically, this study will: (1) develop data-driven clinical classification criteria for ARHL; (2) create a personalized \"Hearing Health Clock\" predictive model; (3) identify minimally invasive blood biomarkers for early detection of cognitive impairment; and (4) formulate a multidimensional early dementia screening program suitable for community-wide implementation. The findings will provide scientific evidence and practical tools for the prevention and control of hearing and cognitive health risks in older adults in China.",[296,318],"Dementia",[318,320,321,322,323],"Hearing Loss","Disease Burden","Cohort Study","Predictive Model","2026-05-20",{"date":209,"type":40},{"date":327,"type":21},"2026-05-25",{"date":122,"type":21},{"name":46,"class":47},{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":337,"targetDuration":4,"studyType":22,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":48},"100638101","phase-2-short-course-online-adaptive-radiotherapy-combined-with-chemotherapy-targeted-therapy-and-immunotherapy-as-total-neoadjuvant-therapy-tnt-for-locally-advanced-rectal-cancer-100638101","NCT07581626","Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer","A Single-Arm, Phase 2 Clinical Study on the Efficacy and Safety of Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer","Inclusion Criteria:\n\n* Voluntarily signed the informed consent form.\n* Aged 18-75 years (inclusive of 18 and 75 years).\n* pMMR\u002FMSS.\n* Middle or low rectal cancer located ≤10 cm from the anal verge as assessed by MRI.\n* Histopathologically confirmed locally advanced rectal adenocarcinoma and high-risk features confirmed by pelvic MRI (meeting any of the following criteria: clinical stage cT3N+ or cT4N0\u002F+; MRF+ or EMVI+; enlarged lateral pelvic lymph nodes).\n* ECOG PS of 0-1.\n* Expected survival ≥2 years.\n* No prior anti-tumor therapy.\n* At least one measurable lesion with a longest diameter ≥10 mm measured by MRI (by RECIST version 1.1).\n* Organ functions meeting the following requirements (no blood products or cell growth factors allowed within 14 days prior to enrollment):\n\nAbsolute neutrophil count ≥1.5×10⁹\u002FL; Platelet count ≥100×10⁹\u002FL; Hemoglobin ≥90 g\u002FL; Total bilirubin \\\u003C1.5×ULN; ALT and\u002For AST \\\u003C2.5×ULN; Serum creatinine \\\u003C1.5×ULN; Creatinine clearance ≥50 mL\u002Fmin.\n\n* Women of childbearing potential must use effective contraceptive measures.\n* Good compliance and willingness to comply with follow-up requirements.\n\nExclusion Criteria:\n\n* Unable to comply with the study protocol or study procedures.\n* Patients with contraindications to surgery.\n* Patients with metastatic disease or recurrent rectal cancer.\n* Uncontrolled active autoimmune disease or active inflammatory disease at enrollment, or receiving immunosuppressive therapy.\n* History of organ transplantation.\n* Known interstitial lung disease (ILD) or unexplained persistent cough and dyspnea.\n* Patients with familial adenomatous polyposis (FAP), hereditary non-polyposis colorectal cancer (HNPCC), active Crohn's disease, or active ulcerative colitis.\n* Other malignancy diagnosed within 5 years prior to enrollment, except for radically resected basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.\n* Severe cardiovascular disease within 6 months prior to enrollment, including unstable angina pectoris or myocardial infarction.\n* Subjects with hypersensitivity to the investigational product or any of its excipients.\n* Participation in another clinical trial of an unapproved\u002Finvestigational drug within 4 weeks prior to enrollment and having received the corresponding investigational product.\n* Clinically significant electrolyte abnormalities judged by the investigator.\n* Uncontrolled hypertension prior to enrollment, defined as systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg despite medication.\n* Poorly controlled diabetes mellitus prior to enrollment (fasting glucose concentration ≥ CTCAE Grade 2 after standard treatment).\n* Any disease or condition affecting drug absorption prior to enrollment, or inability of the patient to take oral medication.\n* Active gastrointestinal diseases such as gastric and duodenal ulcer, ulcerative colitis prior to enrollment, or other conditions judged by the investigator that may cause gastrointestinal bleeding or perforation.\n* Severe active bleeding within 3 months prior to enrollment, hemoptysis (\\>5 mL fresh blood within 4 weeks), or thromboembolic event (including stroke and\u002For transient ischemic attack) within 12 months.\n* Clinically significant cardiovascular disease including but not limited to: acute myocardial infarction, severe\u002Funstable angina pectoris, or coronary artery bypass grafting within 6 months prior to enrollment; congestive heart failure with New York Heart Association (NYHA) classification \\> Grade 2; ventricular arrhythmia requiring pharmacotherapy; left ventricular ejection fraction (LVEF) \\\u003C 50%.\n* Active or uncontrolled severe infection (≥ CTCAE v5.0 Grade 2).\n* Known human immunodeficiency virus (HIV) infection. Known clinically significant liver disease history, including viral hepatitis:\n* Hepatitis B virus (HBV) carriers with active HBV infection (HBV DNA positive: \\>1×10⁴ copies\u002FmL or \\>2000 IU\u002FmL);\n* Known hepatitis C virus (HCV) infection with positive HCV RNA (\\>1×10³ copies\u002FmL).\n* Unresolved toxicities higher than CTCAE v5.0 Grade 1 resulting from any prior anti-cancer therapy, excluding alopecia, lymphopenia, and oxaliplatin-induced neurotoxicity ≤ Grade 2.\n* Female subjects who are pregnant (positive pregnancy test before treatment) or breastfeeding.\n* Urinalysis showing urine protein ≥ 2+ and 24-hour urinary protein \\> 1.0 g.\n* Any other disease, clinically significant metabolic abnormality, physical examination abnormality, or laboratory abnormality that, in the investigator's judgment, renders the patient unsuitable for the study drug (e.g., seizure disorder requiring treatment), interferes with the interpretation of study results, or places the patient at high risk.\n* Patients considered unsuitable for inclusion in this study by the investigator.",{"count":243,"type":21},[135],"Standard treatment for patients with proficient mismatch repair (pMMR) \u002F microsatellite stable (MSS) locally advanced rectal cancer (LARC) consists primarily of neoadjuvant chemoradiotherapy followed by radical surgery. Several studies (including the UNION, STELLAR, TORCH, and SPRING-01 trials, etc) have demonstrated that the neoadjuvant strategy of short-course radiotherapy followed by chemotherapy combined with immunotherapy can improve pCR rate in patients with pMMR\u002FMSS LARC, and might also provide higher organ preservation rates and long-term survival benefits. The study aims to explore the efficacy and safety of a TNT regimen comprising short-course radiotherapy combined with chemotherapy, cetuximab N01 (for patients with wild-type RAS\u002FBRAF) or bevacizumab (for patients with mutant RAS\u002FBRAF), and sintilimab in patients with high-risk LARC.",[341],"Locally Advanced Rectal Cancer (LARC)","2026-05-14",{"date":344,"type":40},"2026-05-18",{"date":346,"type":21},"2026-05-01",{"date":348,"type":21},"2028-04-01",{"name":46,"class":47},{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":241,"enrollmentInfo":357,"targetDuration":4,"studyType":22,"phases":359,"briefSummary":360,"conditions":361,"keywords":363,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":370,"locationsCount":48},"100639236","early-phase-1-the-safety-and-efficacy-of-ksvcbd-injection-in-neuromyelitis-optica-spectrum-disorder-100639236","NCT07592754","The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.","An Early Exploratory Clinical Study on the Safety and Efficacy of KSVCBD Injection in the Treatment of Relapsed\u002FRefractory AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder.","Key Inclusion Criteria:\n\n1. Patients must meet the 2015 International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorder (NMOSD) and test positive for AQP4 antibodies.\n2. Documented evidence of at least 1 relapse within 12 months before signing the informed consent form.\n3. The Expanded Disability Status Scale (EDSS) score ≤ 8.\n4. Female participants of childbearing potential must present a negative pregnancy test at screening and agree to use effective contraception throughout the study period.\n5. Informed consent must be obtained from the patient or their legal representative, with a signed consent form must be provided.\n\nKey Exclusion Criteria:\n\n1. Viral infections: Known HIV, active HBV, or active HCV.\n2. Pregnant or breastfeeding women.\n3. History of other autoimmune diseases requiring immunosuppressive therapy.\n4. Use of any live vaccines against infectious disease within 6 weeks before enrollment.\n5. History of bone marrow\u002Fhematopoietic stem cell or solid organ transplantation.\n6. Patients deemed unsuitable for participation by the investigator.",{"count":358,"type":21},18,[24],"KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This is a multi-center, single-arm, open-label, early exploratory clinical study. The objective of this study is to evaluate the safety and preliminary efficacy of KSVCBD injection in AQP4-positive Neuromyelitis Optica Spectrum Disorder",[362],"Neuromyelitis Optica Spectrum Disease (NMOSD)",[364],"Neuromyelitis Optica Spectrum Disorders","2026-05-12",{"date":344,"type":40},{"date":368,"type":21},"2026-05-15",{"date":255,"type":21},{"name":46,"class":47},{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":264,"enrollmentInfo":379,"targetDuration":381,"studyType":293,"phases":4,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":385,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":4},"100638075","prospective-study-of-high-penetration-super-resolution-transcranial-ultrasound-for-early-identification-of-postoperative-intracranial-metallic-targets-after-aneurysm-clipping-100638075","NCT07583225","Prospective Study of High-penetration Super-resolution Transcranial Ultrasound for Early Identification of Postoperative Intracranial Metallic Targets After Aneurysm Clipping","Clinical Model-Based Evaluation of High-Penetration Super-Resolution Transcranial Ultrasound for Early Diagnosis of Intracranial Metallic Foreign Bodies in Patients After Intracranial Aneurysm Clipping","HPSR-TCUS Clip","Inclusion Criteria:\n\n1. Age 18-85 years;\n2. Positive group: patients undergoing intracranial aneurysm clipping with implanted metallic clips; negative control group: postoperative craniotomy patients without implanted clips;\n3. Ability to complete transcranial ultrasound within 3 hours after surgery;\n4. Availability of postoperative CT;\n5. Written informed consent from the participant or legally authorized representative.\n\nExclusion Criteria:\n\n1. Inability to complete standardized transcranial ultrasound;\n2. Missing postoperative CT;\n3. Inability to establish the composite reference standard;\n4. Presence of non-study-related metallic materials that may substantially interfere with target identification;\n5. Withdrawal of consent;\n6. Investigator judgment that continued participation is inappropriate.",{"count":380,"type":21},78,"1 Day","To evaluate the patient-level early diagnostic performance of high-penetration super-resolution transcranial ultrasound for identifying intracranial metallic targets, and to further assess clip-level detection, localization, agreement, and its complementary value to routine postoperative imaging.This study does not alter routine clinical treatment. All participants will undergo standardized high-penetration super-resolution transcranial ultrasound within 3 hours after surgery. Postoperative CT is mandatory for all participants; CTA or other routine postoperative imaging will be obtained only when clinically indicated.",[384],"Intracranial Aneurysms",{"date":368,"type":40},{"date":387,"type":21},"2026-05-30",{"date":389,"type":21},"2027-04-30",{"name":46,"class":47},{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":293,"phases":4,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":48},"100640238","early-application-of-budesonide-enteric-coated-capsules-in-the-treatment-of-primary-iga-nephropathy-100640238","NCT07585981","Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.","Inclusion Criteria:\n\n* (1) Age ≥ 18 years (2) Primary IgA nephropathy confirmed by renal-biopsy pathology within the past 2 weeks (3) eGFR ≥ 20 mL\u002Fmin\u002F1.73 m² (4) 24-hour urinary protein 0.5-3.5 g\u002Fday (5) Patient has been fully informed, agrees to receive supportive care plus budesonide enteric-coated capsules, and has signed the informed-consent form\n\nExclusion Criteria:\n\n* (1) Secondary IgAN attributable to, but not limited to, Henoch-Schönlein purpura, systemic lupus erythematosus, liver cirrhosis, rheumatoid arthritis, or ankylosing spondylitis (2) Previous renal transplantation or current dialysis (3) Co-existing glomerular disease on biopsy (e.g., C3 glomerulopathy, diabetic nephropathy) or nephrotic syndrome (4) Acute, chronic, or latent infection, including hepatitis, tuberculosis, HIV, or chronic urinary-tract infection (5) Type 1 or type 2 diabetes with poor control (HbA1c \\> 9 %) (6) History of unstable angina, NYHA class III\u002FIV congestive heart failure, or clinically significant arrhythmia (7) Uncontrolled hypertension (systolic ≥ 160 mmHg or diastolic ≥ 90 mmHg) (8) Malignancy diagnosed within the past 5 years (9) Known glaucoma, cataract, or history of cataract surgery (10) Gastro-intestinal disorders that may interfere with drug release or efficacy (peptic-ulcer disease, inflammatory bowel disease, chronic diarrhea) (11) Previous severe adverse reaction to corticosteroids, including psychotic symptoms (12) Concomitant use of potent cytochrome P450 3A4 (CYP3A4) inhibitors (13) Pregnancy, lactation, or unwillingness to use highly effective contraception during treatment and the 3-month follow-up (applies to women of child-bearing potential) (14) Patients whom the investigator deems unsuitable for budesonide enteric-coated-capsule therapy",{"count":58,"type":21},"This multicenter, open-label, prospective single-arm study will enroll adults (≥18 y) with primary IgA nephropathy confirmed by renal biopsy within 2 weeks, eGFR ≥20 ml\u002Fmin\u002F1.73 m² and 0.5-3.5 g\u002Fd proteinuria, to receive early (real-world) combination therapy with RASI (titrated irbesartan), SGLT2i (dapagliflozin 10 mg qd) and budesonide enteric-coated capsules (16 mg qd) for 9 months, followed by budesonide taper-off and continuation of RASI+SGLT2i for 3 more months (12 months total), with primary endpoint being change in proteinuria from baseline to month 12 and secondary endpoints changes in eGFR and microscopic hematuria.",[400],"IgA Glomerulonephritis","2026-05-08",{"date":342,"type":40},{"date":404,"type":40},"2025-10-20",{"date":406,"type":21},"2027-10-01",{"name":46,"class":47},{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":241,"enrollmentInfo":416,"targetDuration":4,"studyType":22,"phases":417,"briefSummary":419,"conditions":420,"keywords":424,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":48},"100638927","phase-4-effectiveness-and-safety-of-acemetacin-in-active-axial-spondyloarthritis-a-real-world-study-100638927","NCT07582146","Effectiveness and Safety of Acemetacin in Active Axial Spondyloarthritis: A Real-world Study","Effectiveness and Safety of Acemetacin in Patients With Active Axial Spondyloarthritis: A Prospective, Multicenter, Observational Real-World Study","ARISE","Inclusion Criteria:\n\n* Subjects who fully understand the purpose and procedures of the trial and voluntarily sign the Informed Consent Form (ICF);\n* Subjects aged 18-65 years (inclusive), regardless of gender;\n* Meet the 2025 ASAS-SPARTAN Revised Classification Criteria for Axial Spondyloarthritis;\n* ASDAS score \\> 2.1.\n\nExclusion Criteria:\n\n* Subjects with known allergy to acemetacin, other NSAIDs, or any excipients;\n* Subjects with active gastrointestinal ulcer\u002Fbleeding, or a history of recurrent ulcer\u002Fbleeding;\n* Subjects with severe cardiac or renal dysfunction, or hepatic dysfunction;\n* Subjects with ulcerative colitis or Crohn's disease;\n* Subjects who received systemic glucocorticoids or intra-articular glucocorticoid injections within 3 months prior to the study start;\n* Subjects who received targeted therapy within 3 months prior to the study start;\n* Any other condition that, in the investigator's opinion, makes the subject unsuitable for participation in this study.",{"count":5,"type":21},[418],"PHASE4","The goal of this observational study is to evaluate the effectiveness and safety of acemetacin in adults (18-65 years) with active axial spondyloarthritis (axSpA) who meet the 2025 ASAS-SPARTAN revised classification criteria and have an ASDAS score greater than 2.1.\n\nThe main questions this study aims to answer are:\n\n* Does acemetacin reduce overall pain assessed by visual analog scale (VAS) after 4 weeks of treatment?\n* What proportion of patients achieve clinical remission (ASDAS ≤1.3) or low disease activity (1.3\\\u003CASDAS≤2.1) at week 4?\n* What medical problems (side effects) occur during acemetacin treatment, with particular attention to gastrointestinal and cardiovascular events?\n\nParticipants will:\n\n* Undergo screening assessments including blood tests, imaging of the sacroiliac joints (MRI, CT, X-ray), and physical examination within 7 days before starting treatment\n* Take acemetacin 90 mg by mouth once daily for 4 weeks\n* Complete a phone follow-up at week 2 and an in-clinic visit at week 4\n* Have pain scores, disease activity measures (ASDAS, BASDAI, BASFI, ASAS HI, BASMI), and laboratory tests (CRP, ESR) recorded at each visit\n* Be monitored for adverse events throughout the treatment period",[421,422,423],"Axial Spondyloarthritis","Axial Spondyloarthritis, Non-Radiographic","Ankylosing Spondylitis (AS) \u002F Radiographic Axial SpA (r-axSpA)",[425,421,426,427],"Acemetacin","NSAIDs","Real-World Study","2026-05-06",{"date":365,"type":40},{"date":431,"type":21},"2026-04",{"date":433,"type":21},"2026-12",{"name":46,"class":47},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":241,"enrollmentInfo":443,"targetDuration":4,"studyType":22,"phases":444,"briefSummary":445,"conditions":446,"keywords":448,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":4},"100639058","phase-2-a-phase-ii-study-of-nb001-for-acute-migraine-treatment-100639058","NCT07577050","A Phase II Study of NB001 for Acute Migraine Treatment","A Phase II, Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NB001 for the Acute Treatment of Migraine","Channel","Inclusion Criteria:\n\n1. The patient is aged ≥18 and ≤65 years at the Screening Visit, of either sex.\n2. The patient has a diagnosis of migraine with aura or migraine without aura as defined by the ICHD-3 criteria confirmed at the Screening Visit.\n3. The patient has had an onset of migraine at \\\u003C50 years of age, with a history of migraine (with or without aura) of at least 1 year prior to the Screening Visit.\n4. According to the investigator's judgment, the patient has had 2 to 8 moderate or severe migraine attacks per month in the 3 months prior to the Screening Visit.\n5. According to the investigator's judgment, the patient's untreated or unsuccessfully treated migraine attacks typically last 4 to 72 hours.\n6. The patient is able to read and understand the Informed Consent Form, and signed the Informed Consent Form.\n7. Women of childbearing potential and male participants must practice strict contraception from screening until 30 days after the last dose.\n8. The patient is capable of adequately understanding and completing the study-related scales and using the electronic patient-reported outcome software.\n\nExclusion Criteria:\n\n1. The patient has a severe allergic constitution, or has known or suspected allergies to the investigational product or its excipients as judged by the investigator.\n2. The patient is unable to distinguish migraine attacks from tension-type headaches or other headaches.\n3. The patient has an average history of ≥15 headache days per month in the 3 months prior to the Screening Visit, or currently meets the ICHD-3 diagnostic criteria for chronic migraine, as judged by the investigator.\n4. The patient has special types of migraine, such as hemiplegic migraine or migraine with brainstem aura.\n5. The patient has other complex pain syndromes, complex psychiatric disorders, dementia, epilepsy, or other significant neurological disorders as judged by the investigator.\n6. The patient has a chronic, non-headache pain condition requiring daily pain medication.\n7. The patient has clinically significant cardiovascular, cerebrovascular, hematological, endocrine, pulmonary, renal, hepatic, gastrointestinal, psychiatric, or neurological disorders.\n8. The patient has a history of malignancy within 5 years prior to the Screening Visit, with the exception of adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix.\n9. The patient has any prior history of gastrointestinal disease that may affect the absorption or metabolism of the study drug, or has a recent history of diarrhea.\n10. The patient has active peptic ulcers, chronic gastrointestinal inflammation, or severe hemorrhoids (Grade III-IV internal hemorrhoids or bleeding external hemorrhoids).\n11. The patient has tested positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, Treponema pallidum antibodies (TPHA), or human immunodeficiency virus (HIV) antibodies at the Screening Visit.\n12. The patient has hepatic dysfunction: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥1.5 × upper limit of normal; estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73 m² (calculated using the simplified MDRD formula); or creatine kinase \\>2.0 × ULN.\n13. The patient has a 12-lead ECG result at the Screening Visit showing QTcF \\>450 msec in males or \\>470 msec in females.\n14. The patient has a suspected or confirmed history of alcohol or drug abuse.\n15. The patient has a positive pregnancy test, is pregnant or breastfeeding, or is planning to become pregnant.\n16. The patient has participated in another clinical trial within 1 month prior to the Screening Visit.\n17. Subjects deemed by the investigator as inappropriate for enrollment in this clinical study.",{"count":133,"type":21},[135],"The goal of this observational study is to Evaluate the Efficacy and Safety of NB001 for the Acute Treatment of Migraine in Adult patients diagnosed with migraine.",[447],"Migraine",[447],"2026-05-05",{"date":451,"type":40},"2026-05-11",{"date":453,"type":21},"2026-04-20",{"date":455,"type":21},"2026-12-31",{"name":46,"class":47},{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":17,"minAge":464,"maxAge":465,"enrollmentInfo":466,"targetDuration":4,"studyType":22,"phases":467,"briefSummary":468,"conditions":469,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":471,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":477},"100553103","phase-1-tcr-reserved-and-power3-sppl3-gene-knock-out-allogeneic-cd19-targeting-car-t-cell-therapy-in-rr-b-all-100553103","NCT06481735","TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r\u002Fr B-ALL","A Phase 1\u002F2 Multicenter Study Evaluating the Safety and Efficacy of TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in Adults With Refractory\u002FRelapsed B-cell Acute Lymphoblastic Leukaemia","Inclusion Criteria:\n\n1. Age 16-70 (inclusive).\n2. Patient with r\u002Fr CD19+ B-ALL, as per guidelines (NCCN, 2019)\n\n   * For patients with bone marrow involvement, morphologically confirmed with ≥ 5% leukaemic blasts in the bonemarrow.\n   * Definition of relapsed disease: Bone marrow or extramedullary relapse after achieving CR with initial treatment, or any bone marrow or extramedullary relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT).\n   * Refractory disease is defined by not achieving an initial CR after 2 cycles of a standard chemotherapy regimen (primary refractory). Subjects who were refractory to subsequent chemotherapy regimens after an initial remission were considered chemorefractory.\n3. Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1 (except for hematological toxicities and clinically non-significant toxicities such as alopecia).\n4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n5. Adequate renal, hepatic, pulmonary and cardiac function defined as:\n\n   * Serum creatinine≤1.5 upper limit of normal (ULN) or creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL\u002Fmin.\n   * Serum alanine aminotransferase \u002F aspartate aminotransferase (ALT\u002FAST) ≤ 3 upper limit of normal (ULN); Total bilirubin ≤ 1.5 ULN, except in subjects with 3) Gilbert's syndrome.\n   * Cardiac ejection fraction ≥ 50%, no evidence of pericardial effusion as determined by an echocardiogram (ECHO), and no clinically significant electrocardiogram (ECG) findings.\n   * Coagulation Function: International Normalized Ratio (INR) ≤ 1.5 times the upper limit of normal (ULN), and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 times ULN.\n   * Baseline oxygen saturation \\>91% on room air.\n6. Subjects of both genders who are willing to practice birth control from the time of consent through 6 months after the completion of conditioning chemotherapy. Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential).\n7. Voluntarily participate in this clinical trial and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Expected survival time \\\u003C 3 months per Principal Investigator's opinion.\n2. History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) unless disease free for at least 3 years.\n3. Patients who received any immunocellular or HSCT therapy within 3 months before enrollment.\n4. Active central nervous system (CNS) leukaemia (CNS-3).\n5. Clinically active significant CNS dysfunction.\n6. Known history of irreversible severe neurological toxicity related to previous antileukaemic treatment leading to organic central nervous system lesions.\n7. Use of previous anti-leukemic therapy within 5 half-lives prior to allogeneic Power3 (SPPL3) knock-out CD19 CAR-T administration; participation in non-interventional registries or epidemiological studies is allowed.\n8. Radioimmunotherapy, radiotherapy, within 8 weeks (except prophylaxis of CNS involvement) before Inclusion.\n9. History of severe immediate hypersensitivity reaction to any of the agents or any component used in this study.\n10. Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous (IV) antimicrobials for management.\n11. Uncontrolled or active infectious diseases, such as human immunodeficiency virus (HIV) infection, acute or chronic active hepatitis B or C, epstein-barr virus (EBV), and cytomegalovirus (CMV) infection.\n12. History or presence of CNS disorder such as seizure disorder, cerebrovascular ischemia\u002Fhemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement.\n13. Subjects with cardiac atrial or cardiac ventricular lymphoma involvement.\n14. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment.\n15. Expected or possible requirement for urgent therapy within 6 weeks due to ongoing or impending oncologic emergency (eg, tumor mass effect, tumor lysis syndrome).\n16. Primary immunodeficiency.\n17. History of autoimmune disease (e.g. Crohn's, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression\u002Fsystemic disease modifying agents within the last 2 years.\n18. History of symptomatic deep vein thrombosis or pulmonary embolism requiring systemic anticoagulation within 6 months of enrollment.\n19. Any medical condition likely to interfere with assessment of safety or efficacy of study treatment.\n20. Vaccine ≤ 6 weeks prior to planned start of conditioning regimen.\n21. Presence of DSAs directed against allogeneic SPPL3 knock-out CD19 CAR-T.\n22. In the investigator's judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.","16 Years","70 Years",{"count":58,"type":21},[161,135],"The safety and efficacy of the chimeric antigen receptor (CAR)-T, a CD19-targeting, TRAC and Power3 (SPPL3) double gene deleted allogeneic CAR-T cell product, are undergoing rigorous evaluation in non-Hodgkin's lymphoma (NHL) subjects from the ATHENA trial (NCT06014073). Unexpectedly, expansion of the initial residual CD3-positive CAR T from products were measured in patients' peripheral blood (PB) without exception. Accompanying with host immune reconstitution and appearance of the detectable B cells, the CD3-positive allogenic CAR T cells exhibited a compelling amplification advantage over CD3-negative CAR T cells. The amplification of CD3-positive CAR T cell population dynamically suppressed host B cell recovery, and presumably surveilled the recurrence or progression of tumors, but did not induce typical Graft-versus-host-disease (GvHD). Additionally, a series of in vitro experiments illustrated that the human leukocyte antigen (HLA)-mismatched fratricide between host T cells and TCR-reserved Power3 (SPPL3)-deleted allogenic CAR T cells was markedly slashed, which in combination with investigators' observed clinical safety data supported the notion that only genomic deletion of Power3 (SPPL3) gene in allo-CAR T cells is sufficient to overcome GvHD and host T cell-mediated rejection response.\n\nIn this study, investigators will disable the Power3 (SPPL3) gene of T cells from healthy donors to prepare CAR T cells (purified CAR-positive T cells \\> 90%). This approach harnesses the tonic signaling of CAR T cells, resulting in enhanced persistence and improved response to treatment. The purpose of this study is to evaluate the safety and efficacy of allogeneic Power3 (SPPL3) knock-out CD19 CAR-T in B-cell acute lymphoblastic leukaemia (B-ALL).",[470],"Acute Lymphocytic Leukemia",{"date":401,"type":40},{"date":473,"type":40},"2025-02-15",{"date":475,"type":21},"2028-02-15",{"name":46,"class":47},6,{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":17,"minAge":485,"maxAge":56,"enrollmentInfo":486,"targetDuration":4,"studyType":22,"phases":488,"briefSummary":489,"conditions":490,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":48},"100587437","phase-2-a-multicenter-rct-of-37-vs-venetoclax--cacag-in-newly-diagnosed-midhigh-risk-aml-patients-100587437","NCT06928376","A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid\u002FHigh-Risk AML Patients","A Multicenter, Prospective, Randomized Controlled Study of the Standard \"3+7\" Regimen Versus Venetoclax Combined With CACAG Regimen in Newly Diagnosed Adult Patients With Intermediate- and High-risk Acute Myeloid Leukemia","Inclusion Criteria:\n\nAge 14 to 75 years (no gender limitation) Newly diagnosed with intermediate- or high-risk AML (excluding M3) Liver function: ALT and AST ≤ 2.5 times upper limit of normal; bilirubin ≤ 2 times upper limit of normal Renal function: creatinine ≤ upper limit of normal No uncontrolled infections, organ dysfunction, or severe mental illness ECOG performance status score of 0-2 and predicted survival ≥ 4 months No severe allergic constitution\n\nExclusion Criteria:\n\nAllergy or contraindication to the study drug Pregnant or breastfeeding female patients Known history of alcohol or drug addiction (due to potential non-compliance) Mental illness or conditions preventing protocol compliance Less than 6 weeks after major organ surgery Liver function: ALT and AST \\> 2.5 times upper limit of normal; bilirubin \\> 2 times upper limit of normal Renal function: creatinine \\> upper limit of normal Deemed unsuitable for the clinical trial (poor compliance, substance abuse, etc.)\n\n\\-","14 Years",{"count":487,"type":21},160,[135],"The purpose of this study is to compare the efficacy and safety of venetoclax combined with the CACAG regimen with the traditional \"3+7\" regimen in the treatment of newly diagnosed intermediate- or high-risk acute myeloid leukemia (AML).",[142,491],"First Line Therapy","2026-05-04",{"date":401,"type":40},{"date":495,"type":40},"2024-04-18",{"date":497,"type":21},"2026-09-01",{"name":46,"class":47},{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":83,"enrollmentInfo":506,"targetDuration":4,"studyType":293,"phases":4,"briefSummary":508,"conditions":509,"keywords":514,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":48},"100635832","efficacy-of-thermal-ablation-combined-with-antithyroid-drugs-in-the-treatment-of-primary-hyperthyroidism-100635832","NCT07557810","Efficacy of Thermal Ablation Combined With Antithyroid Drugs in the Treatment of Primary Hyperthyroidism","Multicenter Study on the Efficacy of Thermal Ablation Combined With Antithyroid Drugs in the Treatment of Primary Hyperthyroidism","Inclusion Criteria:\n\n* Patients diagnosed with primary hyperthyroidism based on clinical manifestations and laboratory findings;\n* Patients whose basal metabolic rate (BMR) remains within ±20% of the normal reference range, and whose resting heart rate is controlled at ≤90 beats\u002Fmin;\n* Patients with inadequate response to standard antithyroid drug (ATD) therapy, those experiencing severe adverse reactions to ATDs, those unsuitable for or unresponsive to radioactive iodine (RAI) therapy, or those who decline conventional surgical resection and wish to undergo ablation combined with medication to shorten the treatment course and achieve rapid improvement of hyperthyroid symptoms, including patients with mild, moderate, or severe disease;\n* Patients with concomitant moderate-to-severe Graves' ophthalmopathy (GO);\n* Patients with a safe needle trajectory for ablation access;\n* Patients who are able to understand the purpose of the study, voluntarily participate, and provide written informed consent.\n\nExclusion Criteria:\n\n* Severe coagulopathy;\n* Poor general condition, such as concomitant severe cardiac, hepatic, renal, or other major organ dysfunction;\n* Substernal goiter or a thyroid gland largely located in the retrosternal space (relative contraindication; staged treatment may be considered);\n* Patients with malignant exophthalmos in whom the condition may worsen post-procedure;\n* Patients with significant tracheal compression requiring urgent decompression;\n* Unilateral vocal cord dysfunction confirmed by laryngoscopy;\n* Women in the first or third trimester of pregnancy, lactating women, or those planning pregnancy in the near future.",{"count":507,"type":21},454,"Hyperthyroidism is a clinical syndrome caused by excessive production of thyroid hormones, leading to accelerated metabolism and increased excitability of multiple organ systems. Patients commonly present with polyphagia, weight loss, palpitations, and sweating. Primary hyperthyroidism is a common endocrine disorder traditionally treated with anti-thyroid drugs (ATD), radioactive iodine (¹³¹I), or surgery.\n\nWhile ATD can rapidly inhibit thyroid hormone synthesis and control symptoms, long-term use carries risks of liver damage and bone marrow suppression. Radioactive iodine involves risks of recurrence or permanent hypothyroidism, and thyroidectomy-though effective-is associated with significant trauma, potential complications, and cervical scarring. Given the limitations of these monotherapies, a combined approach leveraging thermal ablation as an adjunct to antithyroid drug therapy has emerged as a promising strategy for both rapid symptom control and long-term management.\n\nWith advances in minimally invasive techniques, thermal ablation combined with pharmacotherapy offers a balanced solution. Thermal ablation-including microwave and radiofrequency ablation-provides high precision, minimal invasiveness, and rapid recovery by directly destroying hyperfunctioning thyroid tissue under ultrasound guidance. When paired with a tailored antithyroid drug regimen, this approach not only secures immediate stabilization of thyroid function but also reduces the required drug dosage and duration, thereby mitigating drug-related adverse effects. This combined strategy maintains the cosmetic and cost-effective advantages of ablation while addressing the need for sustained endocrine control.\n\nStudies have demonstrated that thermal ablation combined with antithyroid drugs effectively normalizes T3 and T4 levels, alleviates hypermetabolic symptoms such as palpitations and sweating, and significantly improves quality of life with a low complication rate. This integrated model is suitable for initial treatment, recurrent or refractory cases, and is particularly advantageous for patients with reduced cardiopulmonary reserve or advanced age.\n\nHowever, current evidence is largely derived from single-center studies, and high-quality multicenter data are needed to validate this combined strategy. This study aims to prospectively collect baseline data from patients undergoing thermal ablation in conjunction with antithyroid drug therapy across multiple centers. The objectives are to evaluate the efficacy and safety of this combined modality, explore the factors influencing the prognosis of ablation in a medicated context, optimize postoperative medication adjustment protocols, and provide high-quality evidence to guide the standardization and clinical dissemination of this synergistic approach.",[510,511,512,513],"Complication Rate","Efficacy and Safety","Hyperthyroidism\u002FThyrotoxicosis","Cure Rate",[515],"Thermal Ablation","2026-04-25",{"date":518,"type":40},"2026-04-29",{"date":520,"type":40},"2025-02-13",{"date":522,"type":21},"2029-12-01",{"name":46,"class":47},{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":17,"minAge":531,"maxAge":241,"enrollmentInfo":532,"targetDuration":4,"studyType":22,"phases":534,"briefSummary":535,"conditions":536,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":48},"100446037","phase-2-ruxolitinib-and-chidamide-intensified-bucy-conditioning-regimen-100446037","NCT05088226","Ruxolitinib and Chidamide Intensified Bu\u002FCY Conditioning Regimen","Ruxolitinib and Chidamide Intensified Bu\u002FCY Conditioning Regimen for Patients With Acute B Cell Lymphoblast Leukemia Underwenting Haploidenticl Peripheral Blood Stem Cell Transplantation","Inclusion Criteria:\n\n1. high risk acute B cell lymphoblastic leukemia with the indications for allogeneic transplantation;\n2. Have matched sibling donors, ≥8\u002F10 HLA matched unrelated donors or haploidentical donors\n3. All patients should aged 12 to 65 years;\n4. Liver function: ALT and AST≤2.5 times the upper limit of normal , bilirubin≤2 times the upper limit of normal;\n5. Renal function: creatinine ≤the upper limit of normal;\n6. Patients without any uncontrolled infections , without organ dysfunction or without severe mental illness;\n7. Eastern Cooperative Oncology Group (ECOG) performance status ≤2;\n8. Have signed informed consent.\n\nExclusion Criteria:\n\n1. pregnant women;\n2. Patients with mental illness or other states unable to comply with the protocol;\n3. ALL patients with Ph positive;","12 Years",{"count":533,"type":21},50,[135],"The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Chidamide intensified conditioning regimen in patients with Acute B cell Lymphoblast leukemia Underwenting Haploidenticl Peripheral blood Stem Cell Transplantation.",[537],"Peripheral Blood Stem Cell Transplantation","2026-04-22",{"date":540,"type":40},"2026-04-23",{"date":542,"type":40},"2021-12-01",{"date":544,"type":21},"2031-06-01",{"name":46,"class":47},{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":553,"targetDuration":4,"studyType":293,"phases":4,"briefSummary":555,"conditions":556,"keywords":558,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":565,"leadSponsor":567,"locationsCount":48},"100634201","predictive-role-of-photon-counting-computed-tomography-in-acute-coronary-syndrom-patients-100634201","NCT07536607","Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients","Prospective Study ofPhoton Counting Computed Tomography in Acute Coronary Syndrom Patients","Inclusion Criter:\n\n* Adult patients (≥18 years) with clinically diagnosed coronary artery disease or undergoing CCTA for chest pain\u002Fheart failure symptoms.\n\n  * Able and willing to provide informed consent and complete scheduled follow-up visits.\n\nExclusion Criteria:\n\n* History of iodine contrast agent allergy.\n* Severe renal insufficiency (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n* History of prior coronary artery bypass grafting (CABG).\n* Pregnant or lactating women",{"count":554,"type":21},180,"For patients with severe calcification or complex non-calcified plaques, we investigate wether PCCT can enable non-invasive, in vivo precise differentiation and quantitative measurement of plaque components (e.g., spotty calcification, necrotic core, fibrous tissue). Further we also study wether these quantitative imaging features can independently predict the risk of MACE in the short term and long term",[557],"Coronary Artery Disease",[559,560],"photon-counting detector CT","coronary artery disease","2026-04-11",{"date":563,"type":40},"2026-04-17",{"date":453,"type":21},{"date":566,"type":21},"2028-12-01",{"name":46,"class":47},{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":575,"targetDuration":4,"studyType":293,"phases":4,"briefSummary":577,"conditions":578,"keywords":580,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":585,"completionDateStruct":586,"leadSponsor":588,"locationsCount":48},"100633311","chinese-overweight-or-obesity-real-world-registry-study-100633311","NCT07525037","Chinese, Overweight or Obesity, Real-World Registry Study","Chinese Registry of Overweight or Obesity, a Multicenter Real-World Registry Study on Clinical Management - CROWN Study","Inclusion Criteria:\n\nAccording to local regulations, the subjects included in the study should meet the following criteria:\n\n1. Male or female patients aged 18 years or above\n2. Diagnosed with overweight or obesity, with a BMI of ≥ 24 kg\u002Fm²\n3. Willing and able to use weight management apps\n4. Willing and able to provide a written informed consent for participating in the study\n5. Patients who meet the instructions for weight loss medication and have no contraindications to non-pharmacological treatments -\n\nExclusion Criteria:\n\n1. Having life-threatening comorbidities, with an expected lifespan of less than one year.\n2. Participating in an interventional trial that requires informed consent.\n3. Engaging in other organized weight loss programs or other clinical trials.\n4. Researchers identify any situation that may endanger the safety or compliance of the subjects.\n\n   \\-",{"count":576,"type":21},10000,"This study will enroll 10,000 patients with obesity, with the participation of approximately 50 medical institutions nationwide. At baseline, demographic data, physical examinations, multiple laboratory tests (including complete blood count, urinalysis, liver\u002Frenal function, electrolytes, thyroid function panel \\[3 items\\], urine albumin\u002Fcreatinine ratio, fasting glucose, fasting C-peptide, fasting insulin, HbA1c, blood lipids, etc.) and hepatic elasticity ultrasound will be performed. Patients will receive weight-loss therapy in routine clinical practice. Data on clinic visits, adverse events, and changes in therapeutic regimens will be centrally collected by investigators or their authorized representatives at Week 26 and Week 52.",[579],"Obesity Type 2 Diabetes Mellitus",[581,579],"Real world study","2026-04-10",{"date":584,"type":40},"2026-04-13",{"date":387,"type":21},{"date":587,"type":21},"2027-12",{"name":46,"class":47},""]